MAIA - AMEX
MAIA Biotechnology, Inc.
$1.50
+4.9%MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
At a Glance
Live Snapshotmaia
Cash at Beginning of Period
Last Annual Value
9.60M
3-Year CAGR
-3%
5-Year CAGR
41%
10-Year CAGR
%
MAIA Biotechnology, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
MAIA Biotechnology, Inc. AMEX:MAIA | 9.60M | -4.3% | 70.6% | N/A | |
 Annovis Bio, Inc. NYSE:ANVS | 10.55B | 619.1% | 320.0% | N/A | |
 CalciMedica, Inc. NASDAQ:CALC | 5.53M | 55.3% | -30.2% | N/A | |
 BioAtla, Inc. NASDAQ:BCAB | 111.47M | -19.7% | -14.1% | N/A | |
 Elutia Inc. NASDAQ:ELUT | 13.24M | -8.0% | -19.7% | N/A |
MAIA Biotechnology, Inc. Fair Value Envelope
Related Guides
Continue your MAIA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.